Related Experiment Video
Updated: May 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal denervation for treatment-resistant hypertension
Sebastian Mafeld1, Nikhil Vasdev, Philip Haslam
1Department of Radiology, Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK. sebastian.mafeld@gmail.com
Unlabelled:
Hypertension is a major public health concern that is increasing in prevalence. Lifestyle and pharmacological management are not always sufficient to control blood pressure and treatment-resistant hypertension is a recognized clinical challenge. Renal sympathetic denervation (RSD) represents a new frontier in the treatment of resistant hypertension.
Results:
from the Symplicity HTN-1 and HTN-2 trials have demonstrated evidence that suggests RSD can safely reduce blood pressure in patients with this condition. More research is needed to verify these data, clarify unanswered questions and assess future applications of RSD. This review provides a detailed overview on the history of hypertension, treatment-resistant hypertension, the rationale behind RSD, current evidence and potential future applications of RSD. An overview of current and upcoming RSD devices is also included.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Action of Diuretics
